PhRMA

06/09/2026

Patients in other high-income countries have access to just 36% of new medicines, while U.S. patients have access to 88%.

That gap reflects policy choices. Systems that undervalue innovation delay or restrict access, leaving patients waiting.

Policies like Most Favored Nation price controls threaten our innovation ecosystem and patients’ access to new medicines.

https://ow.ly/HNE050Z9mC7

06/08/2026

Innovation starts with long-term commitment.

Kyowa Kirin is investing in the future of American biopharmaceutical innovation through expanded U.S. manufacturing capabilities, helping strengthen supply chain resilience and supporting patient access to life-changing medicines.

From antibody research to cell and gene therapies, biopharmaceutical companies are advancing groundbreaking treatments for patients facing rare and serious diseases while creating jobs, driving investment and building for sustainable growth here in the United States.

06/07/2026

Today is National Cancer Survivors Day, a time to celebrate life, honor resilience and look ahead at the incredible science bringing hope to millions.

In the early 2000s, immunotherapy was met with skepticism. Fast forward to today, and it has completely redefined the landscape of oncology. According to a case study, more than 30 immunotherapy drugs have been approved since 2010 to treat 25 different types of cancer.

From therapeutic vaccines, CAR-T cell therapies and new radiopharmaceuticals, these breakthroughs aren’t just advancing science—they are directly translating into more milestones, more birthdays and more time spent with loved ones.

Hear from some of our companies on the future of cancer treatments and the investments being made to deliver new treatments and new tomorrows for so many patients.

https://ow.ly/PAyi50Z89tp

06/06/2026

Cell and gene therapies are transforming how we treat and prevent disease, offering new hope for patients facing serious and rare conditions.

But too many Medicare patients still face barriers to accessing these innovative treatments.

As scientific innovation advances, our health care system must evolve alongside it so patients can benefit from the latest breakthroughs in medicine.

https://ow.ly/3p1o50Z893e

06/05/2026

June is Alzheimer’s & Brain Awareness Month — a time to recognize the millions of patients, families and caregivers impacted by Alzheimer’s disease and renew our commitment to advancing new treatments and cures.

For decades, Alzheimer’s was considered one of medicine’s greatest challenges. Today, scientific innovation is changing what’s possible.

Recent FDA approvals for Alzheimer’s treatments show what’s possible when researchers, regulators and innovators work together with urgency on behalf of patients. FDA’s review pathways and designations helped speed promising therapies through development and review — bringing new options to patients faster while maintaining rigorous standards for safety and effectiveness.

A fast, science-based and predictable regulatory ecosystem matters — especially for patients facing diseases with enormous unmet need.

Continued innovation in neuroscience depends on:
🧠 Strong investment in research and development
⚖️ A fast, science-based and predictable regulatory ecosystem
🔬 Policies that support continued medical innovation
👩‍⚕️ Timely patient access to new treatments

Every breakthrough brings new hope to patients and families waiting for more time and more options.

06/04/2026

On average, it takes 10 to 15 years and $2.6 billion to develop just one medicine, and only 12% of medicines entering clinical trials are successful in getting FDA approval.

IP protections, like patents, empower innovators to take on significant risks in order to develop the best medicines in the world.

Today, there are more than 8,000 medicines in development, providing hope to millions of patients seeking treatment.

06/04/2026

Two decades ago, it took 16 years on average for a new medicine to have two competitors — now it takes an average of just two years.

The result — brand-to-brand competition — can lower the average cost of medicines by as much as 50%.

How strong intellectual property protections lower drug costs, boost competition and accelerate breakthroughs in medicine.

06/04/2026

“Intellectual property doesn’t just protect ideas — it powers American jobs, strengthens local economies, and ensures the U.S. remains a global leader in innovation.”

PhRMA general counsel, Jim Stansel, lays out the far reaching impact of IP for medicine advancement:

This site is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply. By continuing on NOTUS, you agree to its Terms of Use and Privacy Policy.

06/03/2026

Today, American patients enjoy access to more treatment options than anywhere else in the world. What do we have to thank for this success? Two legal foundations: our intellectual property (IP) system and the Hatch-Waxman Act passed in 1984.

To maintain U.S. biopharmaceutical leadership as China rapidly expands its drug discovery and development capabilities, we must preserve the legal framework that drives innovation, lowers costs and expands treatment options for patients.

Read more here: https://ow.ly/UUFu50Z75Ab

06/02/2026

Patients should be able to access lower-cost medicines when they become available.

Since 2014, the three largest PBMs have excluded 1,584% more medicines from commercial formularies, including more generics and biosimilars. These exclusions can limit affordable treatment options and increase out-of-pocket costs for patients.

Policymakers should address anticompetitive PBM practices and help patients benefit from lower-cost medicines.